Mathias V. Schmidt Is There a Common Molecular Link that Drives the Stress Risk for Disease?
© Maximilian Dörrbecker
Max Planck Society
"The Max Planck Society is Germany's most successful research organization. Since its establishment in 1948, no fewer than 18 Nobel laureates have emerged from the ranks of its scientists, putting it on a par with the best and most prestigious research institutions worldwide. The more than 15,000 publications each year in internationally renowned scientific journals are proof of the outstanding research work conducted at Max Planck Institutes – and many of those articles are among the most-cited publications in the relevant field." (Source)
Max Planck Institute of Psychiatry
"The Max Planck Institute of Psychiatry, which focuses primarily on research into depression and anxiety disorders, is one of the world's leading institutes in this field. Here, basic research is closely interlinked with clinical research: the Institute incorporates a 120-bed hospital, numerous specialist outpatient departments and a day unit. Within these facilities, the modern research branches of genetics and proteomics are combined with the clinical analysis techniques of imaging and the measurement of brain function. The aim is to identify biomarkers of psychiatric and neurological disorders in a bid to better understand the molecular basis of these diseases. The knowledge obtained goes into the development of new therapies and drugs for the personalised medicine of tomorrow." (Source)
Almost everybody has to deal with stress sometimes. But what is stress? It is a reaction of the body to a challenging situation which elicits a stress response in the body. Stress is also a risk factor for disease and this is an area that MATHIAS V. SCHMIDT and his research team focus on. The most prominent stress-related disorders are psychiatric disorders and metabolic disorders. Specifically, as Schmidt explains in this video, they ask: Is there a common molecular link that may drive the stress risk for disease? A potential molecular link they found is FKBP51. To test this hypothesis they used FKBP51 knockout animals, their cells and also a pharmacological tool, a FKBP51-specific antagonist. The experiments confirmed that FKBP51 indeed links stress response with an increased risk for metabolic disorders. Their findings can thus be used to develop a drug that can then be tested on humans.
LT Video Publication DOI: https://doi.org/10.21036/LTPUB10600
Stress-Responsive FKBP51 Regulates AKT2-AS160 Signaling and Metabolic Function
- Georgia Balsevich, Alexander S. Häusl, Carola W. Meyer, Stoyo Karamihalev, Xixi Feng, Max L. Pöhlmann, Carine Dournes, Andres Uribe-Marino, Sara Santarelli and Mathias V. Schmidt
- Nature Communications
- Published in 2017